GL0034 (Utreglutide), a long acting, glucagon-like peptide-1 receptor agonist, improves body weight loss, lipid and liver injury markers in individuals with obesity: A phase 1 multiple ascending dose study

被引：0
|
作者：
Thennati, Rajamannar [1 ]
Burade, Vinod [1 ]
Natarajan, Muthukumaran [1 ]
Shahi, Pradeep [1 ]
Nagaraja, Ravishankara [1 ]
Agrawal, Sudeep [1 ]
Jandrain, Bernard [2 ,3 ]
Duvauchelle, Thierry [4 ]
Pratley, Richard E. [5 ]
Thorens, Bernard [6 ]
Vilsboll, Tina [7 ]
Loomba, Rohit [8 ]
机构：
[1] Sun Pharmaceut Ind Ltd, High Impact Innovat Sustainable Hlth Solut HISH, Vadodara, India
[2] Acad Hosp Liege, Clin Pharmacol Unit, ATC Co, Liege, Belgium
[3] Acad Hosp Liege, Div Diabet Nutr & Metab Disorders, Liege, Belgium
[4] Phaster1, Paris, France
[5] AdventHealth Translat Res Inst, Orlando, FL USA
[6] Univ Lausanne, Ctr Integrat Genom, Lausanne, Switzerland
[7] Univ Copenhagen, Steno Diabet Ctr Copenhagen, Clin Res, Copenhagen, Denmark
[8] Univ Calif San Diego, Sch Med, La Jolla, CA USA
来源：
JOURNAL OF HEPATOLOGY | 2024年 / 80卷
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
SAT-231
引用
收藏
页码：S615 / S616
页数：2
相关论文
共 49 条
  • [21] Preliminary observations on the administration of a glucagon-like peptide-1 receptor agonist on body weight and select carbohydrate endpoints in persons with spinal cord injury: A controlled case series
    Cirnigliaro, Christopher M.
    La Fountaine, Michael F.
    Sauer, Susan J.
    Cross, Gregory T.
    Kirshblum, Steven C.
    Bauman, William A.
    JOURNAL OF SPINAL CORD MEDICINE, 2024, 47 (04): : 597 - 604
  • [22] Chronic treatment with glucagon-like peptide-1 and glucagon receptor co-agonist causes weight loss-independent improvements in hepatic steatosis in mice with diet-induced obesity
    McGlone, Emma Rose
    Davies, Iona
    Dore, Marian
    Goldin, Rob
    Jones, Ben
    Liu, Zhigang
    V. Li, Jia
    Vorkas, Panagiotis A.
    Khoo, Bernard
    Carling, David
    Minnion, James
    Bloom, Stephen R.
    Tan, Tricia M. -M.
    BIOMEDICINE & PHARMACOTHERAPY, 2024, 176
  • [23] Differences in weight loss and safety between the glucagon-like peptide-1 receptor agonists: A non-randomized multicenter study from the titration phase
    Seijas-Amigo, Jose
    Salgado-Barreira, Angel
    Castelo-Dominguezh, Rosana
    Perez-Alvarez, Maria Teresa
    Ponce-Pinonj, Belen
    Fernandez-Silva, Marlen
    Rodriguez-Barreiro, Marta
    Pereira-Pia, Mercedes
    Iglesias-Moreno, Jose Manuel
    Gago-Garciao, Mar
    Montans-Garcia, Raquel
    Fernandez-Perez, Agustina
    Fragagayoso, Dolores
    Fernandez-Montenegro, Montse
    Riveiro-Barciela, Beatriz
    Rilla-Villar, Natalia
    Cordero, Alberto
    Rodriguezmanero, Moises
    Gonzalez-Juanatey, Jose R.
    PRIMARY CARE DIABETES, 2023, 17 (04) : 366 - 372
  • [24] A randomized Phase I study of the safety, tolerability, pharmacokinetics and pharmacodynamics of BI 456906, a dual glucagon receptor/glucagon-like peptide-1 receptor agonist, in healthy Japanese men with overweight/obesity
    Yazawa, Rie
    Ishida, Masahiro
    Balavarca, Yesilda
    Hennige, Anita M.
    DIABETES OBESITY & METABOLISM, 2023, 25 (07): : 1973 - 1984
  • [25] Survodutide, a glucagon receptor/glucagon-like peptide-1 receptor dual agonist, improves blood pressure in adults with obesity: A post hoc analysis from a randomized, placebo-controlled, dose-finding, phase 2 trial
    le Roux, Carel W.
    Steen, Oren
    Lucas, Kathryn J.
    Ekinci, Elif I.
    Startseva, Elena
    Unseld, Anna
    Hussain, Samina Ajaz
    Hennige, Anita M.
    DIABETES OBESITY & METABOLISM, 2024,
  • [26] Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1a, blinded, placebo-controlled, randomized, single- and multiple-ascending-dose study in healthy participants
    Pratt, Edward
    Ma, Xiaosu
    Liu, Rong
    Robins, Deborah
    Haupt, Axel
    Coskun, Tamer
    Sloop, Kyle W.
    Benson, Charles
    DIABETES OBESITY & METABOLISM, 2023, 25 (09): : 2634 - 2641
  • [27] Multiple sclerosis patients taking glucagon-like peptide-1 receptor (GLP-1) agonists: a single-institution retrospective cohort study of tolerability and weight loss
    Udawatta, Methma
    Fidalgo, Nicholas
    Mateen, Farrah J.
    NEUROLOGICAL SCIENCES, 2025, 46 (01) : 343 - 349
  • [28] Long-term safety and efficacy of glucagon-like peptide-1 receptor agonists in individuals with obesity and without type 2 diabetes: A global retrospective cohort study
    Huang, Yu-Nan
    Liao, Wen-Ling
    Huang, Jing-Yang
    Lin, Yu-Jung
    Yang, Shun-Fa
    Huang, Chieh-Chen
    Wang, Chung-Hsing
    Su, Pen-Hua
    DIABETES OBESITY & METABOLISM, 2024, 26 (11): : 5222 - 5232
  • [29] Once-daily oral small-molecule glucagon-like peptide-1 receptor agonist lotiglipron (PF-07081532) for type 2 diabetes and obesity: Two randomized, placebo-controlled, multiple-ascending-dose Phase 1 studies
    Buckeridge, Clare
    Tsamandouras, Nikolaos
    Carvajal-Gonzalez, Santos
    Brown, Lisa S.
    Hernandez-Illas, Martha
    Saxena, Aditi R.
    DIABETES OBESITY & METABOLISM, 2024, 26 (08): : 3155 - 3166
  • [30] Orforglipron (LY3502970), a novel, oral non-peptide glucagon-like peptide-1 receptor agonist: A Phase 1b, multicentre, blinded, placebo-controlled, randomized, multiple-ascending-dose study in people with type 2 diabetes
    Pratt, Edward
    DIABETES OBESITY & METABOLISM, 2024, 26 (03): : 1137 - 1137
12345